Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip

International Journal of Cardiology

Volumn 241, Issue , 2017, Pages 302-310

  Luconi, Michaela ^a   Cantini, Giulia ^a   Ceriello, Antonio ^b,c   Mannucci, Edoardo ^a,d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c IRCCS MULTIMEDICA   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cardiovascular outcome trials; Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 receptor agonists; Heart failure; Inflammatory chemokines; MACE

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LINAGLIPTIN; OMARIGLIPTIN; PLACEBO; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; TENELIGLIPTIN; VILDAGLIPTIN; CARDIOTONIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; LIRAGLUTIDE;

ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CORONARY ARTERY BLOOD FLOW; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG EFFICACY; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; REVASCULARIZATION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; AGONISTS; ANIMAL; CARDIOVASCULAR DISEASE; TREATMENT OUTCOME;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HUMANS; INCRETINS; LIRAGLUTIDE; TREATMENT OUTCOME;

EID: 85014665993     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2017.02.126     Document Type: Article

References (68)

1. [1] Control Group, Turnbull, F.M., Abraira, C., Anderson, R.J., Byington, R.P., Chalmers, J.P., Duckworth, W.C., Evans, G.W., Gerstein, H.C., Holman, R.R., Moritz, T.E., Neal, B.C., Ninomiya, T., Patel, A.A., Paul, S.K., Travert, F., Woodward, M., Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52 (2009), 2288–2298.
2. [2] Mannucci, E., Monami, M., Lamanna, C., Gori, F., Marchionni, N., Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr. Metab. Cardiovasc. Dis. 19 (2009), 604–612.
3. [3] Holman, R.R., Paul, S.K., Bethel, M.A., Neil, H.A., Matthews, D.R., Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 359 (2008), 1565–1576.
4. [4] Wilding, J.P., Rajeev, S.P., DeFronzo, R.A., Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm. Diabetes Care 39:Suppl. 2 (2016), S154–S164.
5. [5] No authors, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) group. Lancet 352 (1998), 854–865.
6. [6] Lamanna, C., Monami, M., Marchionni, N., Mannucci, E., Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 13 (2011), 221–228.
7. [7] Phung, O.J., Schwartzman, E., Allen, R.W., Engel, S.S., Rajpathak, S.N., Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet. Med. 30 (2013), 1160–1171.
8. [8] Monami, M., Genovese, S., Mannucci, E., Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 15 (2013), 938–953.
9. [9] Varvaki Rados, D., Catani Pinto, L., Reck Remonti, L., Bauermann Leitão, C., Gross, J.L., The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med., 13, 2016, e1001992.
10. [10] ORIGIN Trial Investigators, Gerstein, H.C., Bosch, J., Dagenais, G.R., Díaz, R., Jung, H., Maggioni, A.P., Pogue, J., Probstfield, J., Ramachandran, A., Riddle, M.C., Rydén, L.E., Yusuf, S., Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367 (2012), 319–328.
11. [11] Dormandy, J., Bhattacharya, M., AR, van Troostenburg de Bruyn, PROactive investigators, Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 32 (2009), 187–202.
12. [12] Zinman, B., Lachin, J.M., Inzucchi, S.E., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 374, 2016, 1094.
13. [13] Vilsbøll, T., Christensen, M., Junker, A.E., Knop, F.K., Gluud, L.L., Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ, 344, 2012, d7771.
14. [14] Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S.D., Hoffman, E.B., Cavender, M.A., Udell, J.A., Desai, N.R., Mosenzon, O., DK, McGuire, Ray, K.K., Leiter, L.A., Raz, I., SAVOR-TIMI 53 Steering Committee and Investigators, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369 (2013), 1317–1326.
15. [15] White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., Perez, A.T., Fleck, P.R., Mehta, C.R., Kupfer, S., Wilson, C., Cushman, W.C., Zannad, F., EXAMINE Investigators, Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369 (2013), 1327–1335.
16. [16] Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., Josse, R., Kaufman, K.D., Koglin, J., Korn, S., Lachin, J.M., McGuire, D.K., Pencina, M.J., Standl, E., Stein, P.P., Suryawanshi, S., Van de Werf, F., Peterson, E.D., Holman, R.R., TECOS Study Group, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373 (2015), 232–242.
17. [17] Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., Fleck, P.R., Mehta, C.R., Kupfer, S., Wilson, C., Lam, H., White, W.B., EXAMINE Investigators, Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
18. [18] Mannucci, E., Mosenzon, O., Avogaro, A., Analyses of results from cardiovascular safety trials with DPP-4 inhibitors: cardiovascular outcomes, predefined safety outcomes, and pooled analysis and meta-analysis. Diabetes Care 39:Suppl. 2 (2016), S196–S204.
19. [19] Monami, M., Dicembrini, I., Mannucci, E., Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr. Metab. Cardiovasc. Dis. 24 (2014), 689–697.
20. [20] Savarese, G., Perrone-Filardi, P., D'Amore, C., Vitale, C., Trimarco, B., Pani, L., Rosano, G.M., Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis. Int. J. Cardiol. 181 (2015), 239–244.
21. [21] Dicembrini, I., Mannucci, E., Risk of myocardial infarction in trials with dipeptidyl peptidase-4 inhibitors: is duration of study a real issue?. Int. J. Cardiol. 184 (2015), 543–544.
22. [22] Fadini, G.P., de Kreutzenberg, S.V., Gjini, R., Avogaro, A., The metabolic syndrome influences the response to incretin-based therapies. Acta Diabetol. 48 (2011), 219–225.
23. [23] Wang, K.L., Liu, C.J., Chao, T.F., Huang, C.M., Wu, C.H., Chen, S.J., Yeh, C.M., Chen, T.J., Lin, S.J., Chiang, C.E., Sitagliptin and the risk of hospitalization for heart failure: a population-based study. Int. J. Cardiol. 177 (2014), 86–90.
24. [24] Filion, K.B., Azoulay, L., Platt, R.W., Dahl, M., Dormuth, C.R., Clemens, K.K., Hu, N., Paterson, J.M., Targownik, L., Turin, T.C., Udell, J.A., Ernst, P., CNODES Investigators, A multicenter observational study of incretin-based drugs and heart failure. N. Engl. J. Med. 374 (2016), 1145–1154.
25. [25] Fadini, G.P., Avogaro, A., Degli Esposti, L., Russo, P., Saragoni, S., Buda, S., Rosano, G., Pecorelli, S., Pani, L., OsMed Health-DB Network, Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur. Heart J. 36 (2015), 2454–2462.
26. [26] Li, L., Li, S., Deng, K., Liu, J., Vandvik, P.O., Zhao, P., Zhang, L., Shen, J., Bala, M.M., Sohani, Z.N., Wong, E., Busse, J.W., Ebrahim, S., Malaga, G., Rios, L.P., Wang, Y., Chen, Q., Guyatt, G.H., Sun, X., Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ, 352, 2016, i610.
27. [27] Fadini, G.P., Avogaro, A., Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vasc. Pharmacol. 55 (2011), 10–16.
28. [28] Devin, J.K., Pretorius, M., Nian, H., Yu, C., Billings, F.T. 4th, Brown, N.J., Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension 63 (2014), 951–957.
29. [29] Devin, J.K., Pretorius, M., Nian, H., Yu, C., Billings, F.T. IV, Brown, N.J., Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm. J. Am. Heart Assoc., 3, 2014 (pii: e001075).
30. [30] Shimizu, H., Masuta, K., Aono, K., Asada, H., Sasakura, K., Tamaki, M., Sugita, K., Yamada, K., Molecular forms of human brain natriuretic peptide in plasma. Clin. Chim. Acta 316 (2002), 129–135.
31. [31] Gomez, N., Touihri, K., Matheeussen, V., Mendes Da Costa, A., Mahmoudabady, M., Mathieu, M., Baerts, L., Peace, A., Lybaert, P., Scharpé, S., De Meester, I., Bartunek, J., Vanderheyden, M., Mc Entee, K., Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur. J. Heart Fail. 14 (2012), 14–21.
32. [32] Sauvé, M., Ban, K., Momen, M.A., Zhou, Y.Q., Henkelman, R.M., Husain, M., Drucker, D.J., Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59 (2010), 1063–1073.
33. [33] Huisamen, B., Genis, A., Marais, E., Lochner, A., Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc. Drugs Ther. 25 (2011), 13–20.
34. [34] Wang, X., Ding, Z., Yang, F., Dai, Y., Chen, P., Theus, S., Singh, S., Budhiraja, M., Mehta, J.L., Modulation of myocardial injury and collagen deposition following ischaemia–reperfusion by linagliptin and liraglutide, and both together. Clin. Sci. (Lond.) 130 (2016), 1353–1362.
35. [35] Pujadas, G., De Nigris, V., Prattichizzo, F., La Sala, L., Testa, R., Ceriello, A., The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. Endocrine 56 (2017), 509–520.
36. [36] Kubota, A., Takano, H., Wang, H., Hasegawa, H., Tadokoro, H., Hirose, M., Kobara, Y., Yamada-Inagawa, T., Komuro, I., Kobayashi, Y., DPP-4 inhibition has beneficial effects on the heart after myocardial infarction. J. Mol. Cell. Cardiol. 91 (2016), 72–80.
37. [37] Lee, T.I., Kao, Y.H., Chen, Y.C., Huang, J.H., Hsu, M.I., Chen, Y.J., The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes. Int. J. Cardiol. 168 (2013), 5390–5395.
38. [38] Shah, Z., Pineda, C., Kampfrath, T., Maiseyeu, A., Ying, Z., Racoma, I., Deiuliis, J., Xu, X., Sun, Q., Moffatt-Bruce, S., Villamena, F., Rajagopalan, S., Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vasc. Pharmacol. 55 (2011), 2–9.
39. [39] Mulvihill, E.E., Varin, E.M., Ussher, J.R., Campbell, J.E., Bang, K.W., Abdullah, T., Baggio, L.L., Drucker, D.J., Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice. Diabetes 65 (2016), 742–754.
40. [40] Aghili, N., Devaney, J.M., Alderman, L.O., Zukowska, Z., Epstein, S.E., Burnett, M.S., Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis. Neuropeptides 46 (2012), 367–371.
41. [41] Mann, D.L., Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91 (2002), 988–998.
42. [42] Frangogiannis, N.G., Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm. Res. 53 (2004), 585–595.
43. [43] Altara, R., Manca, M., Hessel, M.H., Gu, Y., van Vark, L.C., Akkerhuis, K.M., Staessen, J.A., Struijker-Boudier, H.A., Booz, G.W., Blankesteijn, W.M., CXCL10 is a circulating inflammatory marker in patients with advanced heart failure: a pilot study. J. Cardiovasc. Transl. Res. 9 (2016), 302–314.
44. [44] Fadini, G.P., Avogaro, A., Potential manipulation of endothelial progenitor cells in diabetes and its complications. Diabetes Obes. Metab. 12 (2010), 570–583.
45. [45] Zaruba, M.M., Theiss, H.D., Vallaster, M., Mehl, U., Brunner, S., David, R., Fischer, R., Krieg, L., Hirsch, E., Huber, B., Nathan, P., Israel, L., Imhof, A., Herbach, N., Assmann, G., Wanke, R., Mueller-Hoecker, J., Steinbeck, G., Franz, W.M., Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4 (2009), 313–323.
46. [46] Connelly, K.A., Advani, A., Zhang, Y., Advani, S.L., Kabir, G., Abadeh, A., Desjardins, J.F., Mitchell, M., Thai, K., Gilbert, R.E., Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: role of stromal cell-derived factor-1α. J. Diabetes 8 (2016), 63–75.
47. [47] Fadini, G.P., Boscaro, E., Albiero, M., Menegazzo, L., Frison, V., de Kreutzenberg, S., Agostini, C., Tiengo, A., Avogaro, A., The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 33 (2010), 1607–1609.
48. [48] Blonde, L., Pencek, R., MacConell, L., Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc. Diabetol., 14, 2015, 12.
49. [49] Mannucci, E., Monami, M., Cardiovascular safety of incretin-based therapies in type 2 diabetes: systematic review of integrated analyses and randomized controlled trials. Adv. Ther. 34 (2017), 1–40.
50. [50] Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., Mannucci, E., Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 16 (2014), 38–47.
51. [51] Nikolaidis, L.A., Mankad, S., Sokos, G.G., Miske, G., Shah, A., Elahi, D., Shannon, R.P., Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004), 962–965.
52. [52] Sokos, G.G., Bolukoglu, H., German, J., Hentosz, T., Magovern, G.J. Jr., Maher, T.D., Dean, D.A., Bailey, S.H., Marrone, G., Benckart, D.H., Elahi, D., Shannon, R.P., Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am. J. Cardiol. 100 (2007), 824–829.
53. [53] Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H.E., Kim, W.Y., Mathiasen, A.B., Jørgensen, E., Helqvist, S., Saunamäki, K., Clemmensen, P., Holmvang, L., Thuesen, L., Krusell, L.R., Jensen, J.S., Køber, L., Treiman, M., Holst, J.J., Engstrøm, T., Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33 (2012), 1491–1499.
54. [54] Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Køber, L.V., Lawson, F.C., Ping, L., Wei, X., Lewis, E.F., Maggioni, A.P., JJ, McMurray, Probstfield, J.L., Riddle, M.C., Solomon, S.D., Tardif, J.C., ELIXA Investigators, Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373 (2015), 2247–2257.
55. [55] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., Nissen, S.E., Pocock, S., Poulter, N.R., Ravn, L.S., Steinberg, W.M., Stockner, M., Zinman, B., Bergenstal, R.M., Buse, J.B., LEADER Steering Committee, LEADER Trial Investigators, Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375 (2016), 311–322.
56. [56] Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jódar, E., Leiter, L.A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M.L., Woo, V., Hansen, O., Holst, A.G., Pettersson, J., Vilsbøll, T., SUSTAIN-6 Investigators, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375 (2016), 1834–1844.
57. [57] Cantini, G., Mannucci, E., Luconi, M., Perspectives in GLP-1 research: new targets, new receptors. Trends Endocrinol. Metab. 27 (2016), 427–438.
58. [58] Younce, C.W., Burmeister, M.A., Ayala, J.E., Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am. J. Physiol. Cell Physiol. 304 (2013), C508–C518.
59. [59] Sonne, D.P., Engstrøm, T., Treiman, M., Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia–reperfusion injury in rat heart. Regul. Pept. 146 (2008), 243–249.
60. [60] Noyan-Ashraf, M.H., Momen, M.A., Ban, K., Sadi, A.M., Zhou, Y.Q., Riazi, A.M., Baggio, L.L., Henkelman, R.M., Husain, M., Drucker, D.J., GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58 (2009), 975–983.
61. [61] Younce, C.W., Niu, J., Ayala, J., Burmeister, M.A., Smith, L.H., Kolattukudy, P., Ayala, J.E., Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes. J. Mol. Cell. Cardiol. 76 (2014), 172–176.
62. [62] Moberly, S.P., Mather, K.J., Berwick, Z.C., Owen, M.K., Goodwill, A.G., Casalini, E.D., Hutchins, G.D., Green, M.A., Ng, Y., Considine, R.V., Perry, K.M., Chisholm, R.L., Tune, J.D., Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res. Cardiol., 108, 2013, 365.
63. [63] Ban, K., Noyan-Ashraf, M.H., Hoefer, J., Bolz, S.S., Drucker, D.J., Husain, M., Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117 (2008), 2340–2350.
64. [64] Robinson, E., Tate, M., Lockhart, S., McPeake, C., O'Neill, K.M., Edgar, K.S., Calderwood, D., Green, B.D., McDermott, B.J., Grieve, D.J., Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling. Cardiovasc. Diabetol., 15, 2016, 65.
65. [65] Kim, M., Platt, M.J., Shibasaki, T., Quaggin, S.E., Backx, P.H., Seino, S., Simpson, J.A., Drucker, D.J., GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 19 (2013), 567–575.
66. [66] Ussher, J.R., Baggio, L.L., Campbell, J.E., Mulvihill, E.E., Kim, M., Kabir, M.G., Cao, X., Baranek, B.M., Stoffers, D.A., Seeley, R.J., Drucker, D.J., Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol. Metab. 3 (2014), 507–517.
67. [67] Wohlfart, P., Linz, W., Hübschle, T., Linz, D., Huber, J., Hess, S., Crowther, D., Werner, U., Ruetten, H., Cardioprotective effects of lixisenatide in rat myocardial ischemia–reperfusion injury studies. J. Transl. Med., 11, 2013, 84.
68. [68] Raccah, D., Lixisenatide once daily significantly improves postprandial glucose throughout the day due to diverse mechanistic effects. Expert. Rev. Endocrinol. Metab. 8 (2013), 105–121.